Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of British Columbia

$27,000.00

Characterizing Metabolic Behaviours of Pancreatic Cancer

FY 2024-25

Summary
Pancreatic cancer is the third deadliest cancer in Canada, with the highest mortality rate of all the major cancers. Traditional forms of treatment, including chemotherapy and radiation, only provide modest improvements to patient survival, highlighting the need for novel therapeutic options to improve the devastatingly low survival rates.Cancer is a disease characterized by the ability for cells to grow uncontrollably. To achieve this, cancer cells alter their metabolism, which is the network of chemical reactions that provide the energy required for cell growth and survival. The specific metabolic alterations present in pancreatic cancer tumours remain poorly understood. Identifying these metabolic adaptations could provide insightful information for designing targeted treatments against this form of cancer.Recent findings have revealed that a specific transporter protein, known as SLC38A2, is crucial in fueling pancreatic cancer metabolism by importing essential nutrients into the cell. Advancements in cancer research have facilitated the development of 3-dimensional (3D) cell models derived from real patient tumour biopsies that replicate their architecture and behaviours in a controlled environment. I propose the idea of using these models to further understand the metabolic reprogramming of pancreatic cancer. More specifically, my project aims to (1) utilize these 3D cells to understand how inhibition of SLC38A2 impacts tumour metabolism and (2) characterize stratification patterns of tumour response on a patient-to-patient basis. By understanding these mechanisms, my goal is to advance pancreatic cancer therapeutics and create a foundation for designing various treatment options based on patient-specific metabolic alterations.
Program
Master's Award: Canada Graduate Scholarships
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
529746
Name
Cheung Georgia
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Characterizing Metabolic Behaviours of Pancreatic Cancer
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Liquid-Chromatography Mass Spectrometry; Metabolic Subtypes Of Pdac; Pancreatic Ductal Adenocarcinoma (Pdac); Patient-Derived Pancreatic Tumour Organoids; Pdac Metabolism; Pdac Therapeutic Development; Slc38a2 Amino Acid Transporter; Targeted Metabolomics; Untargeted Metabolomics
Abstract
Pancreatic cancer is the third deadliest cancer in Canada, with the highest mortality rate of all the major cancers. Traditional forms of treatment, including chemotherapy and radiation, only provide modest improvements to patient survival, highlighting the need for novel therapeutic options to improve the devastatingly low survival rates.Cancer is a disease characterized by the ability for cells to grow uncontrollably. To achieve this, cancer cells alter their metabolism, which is the network of chemical reactions that provide the energy required for cell growth and survival. The specific metabolic alterations present in pancreatic cancer tumours remain poorly understood. Identifying these metabolic adaptations could provide insightful information for designing targeted treatments against this form of cancer.Recent findings have revealed that a specific transporter protein, known as SLC38A2, is crucial in fueling pancreatic cancer metabolism by importing essential nutrients into the cell. Advancements in cancer research have facilitated the development of 3-dimensional (3D) cell models derived from real patient tumour biopsies that replicate their architecture and behaviours in a controlled environment. I propose the idea of using these models to further understand the metabolic reprogramming of pancreatic cancer. More specifically, my project aims to (1) utilize these 3D cells to understand how inhibition of SLC38A2 impacts tumour metabolism and (2) characterize stratification patterns of tumour response on a patient-to-patient basis. By understanding these mechanisms, my goal is to advance pancreatic cancer therapeutics and create a foundation for designing various treatment options based on patient-specific metabolic alterations.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Cheung, Georgia
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~